

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Currently Amended) A system for treating a ~~or preventing atherosclerosis, stenosis, restenosis, smooth muscle cell proliferation, occlusive disease, or other abnormal luminal cellular proliferation~~ condition by providing interventional medical care to a patient, comprising:

a local delivery system;

a bioactive agent;

wherein the local delivery system is adapted to locally deliver the bioactive agent to a region of tissue associated with the condition;


wherein the bioactive agent when locally delivered to the region of tissue is adapted to treat or prevent the condition; and

wherein the bioactive agent comprises ~~at least one of CC-1065, duocarmycin, apocynin, RGDV, RGD peptide, resveratrol, a stilbene compound, camptothecin, des-aspartate angiotensin 1 ("DAA-1"), or apoptosis DNA factor ("ADF"),~~ or an analog or derivative thereof, or a pharmaceutically acceptable salt thereof, or a combination or blend thereof.

2. (Original) The system of claim 1, wherein the bioactive agent comprises CC-1065 or an analog or derivative thereof, or pharmaceutically acceptable salt thereof.


3. (Original) The system of claim 1, wherein the bioactive agent comprises duocarmycin or an analog or derivative thereof, or pharmaceutically acceptable salt thereof

4. (Original) The system of claim 1, wherein the bioactive agent comprises apocynin or an analog or derivative thereof, or a pharmaceutically acceptable salt thereof.
5. (Original) The system of claim 1, wherein the bioactive agent comprises RGDfV or an analog or derivative thereof, or a pharmaceutically acceptable salt thereof.
6. (Original) The system of claim 1, wherein the bioactive agent comprises an RGD peptide or an analog or derivative thereof. or a pharmaceutically acceptable salt thereof.
7. (Original) The system of claim I, wherein the bioactive agent comprises resveratrol or an analog or derivative thereof, or a pharmaceutically acceptable salt thereof.
8. (Original) The system of claim 1, wherein the bioactive agent comprises a stilbene compound or an analog or derivative thereof, or a pharmaceutically acceptable salt thereof.
9. (Original) The system of claim 1, wherein the bioactive agent comprises camptothecin or an analog or derivative thereof, or a pharmaceutically acceptable salt thereof.
10. (Original) The system of claim I, wherein the bioactive agent comprises DAA-1 or an analog or derivative thereof, or a pharmaceutically acceptable salt thereof.
11. (Canceled)
12. (Original) The system of claim I, wherein the bioactive agent comprises the following molecule, or an analog or derivative thereof, or a pharmaceutically acceptable salt thereof:




CC-1065

13. (Original) The system of claim 1, wherein the bioactive agent comprises the following molecule, or an analog or derivative thereof, or a pharmaceutically acceptable salt thereof:




Apocynin

14. (Original) The system of claim 1, wherein the bioactive agent comprises at least one of the following molecules, or an analog or derivative thereof, or a pharmaceutically acceptable salt thereof:




15. (Original) The system of claim 1, wherein the bioactive agent comprises the following molecule, or an analog or derivative thereof, or a pharmaceutically acceptable salt thereof:



RGDFV, R: Arginine; G:Glycine; D:Aspartic Acid; f:D-Phenylalanine; V:Valine

16. (Original) The system of claim 1, wherein the bioactive agent comprises the following molecule, or an analog or derivative thereof, or a pharmaceutically acceptable salt thereof:




17. (Original) The system of claim I, wherein the bioactive agent comprises the following molecule, or an analog or derivative thereof, or a pharmaceutically acceptable salt thereof:

Long chain unsaturated fatty acid-linker-CPT(Formula I):

wherein:

the Long-chain unsaturated fatty acid is generally C₁₂-C₂₂ mono or poly unsaturated fatty acids, which include, but are not limited to, palmitoleic acid, oleic acid, linoleic acid, linolenic acid, arachidonic acid, eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA);

CPT is a camptothecin compound with the following general structure (Formula




II):

(Formula II)


R_1 - R_5 are H, halo, OH, NO_2 , NH_2 , alkyl, O-alkyl, NH-alkyl, $\text{N}(\text{alkyl})_2$, and can be the same or different;

when any of R_1 - R_5 is amino, the compounds are the free bases and their acid addition salts, such as HO and H_2SO_4 ; and


the linker is selected from formula (III):



18. (Original) The system of claim I, wherein the bioactive agent comprises at least one of the following molecules, or an analog or derivative thereof, or a pharmaceutically accept-able salt thereof:



19. (Original) The system of claim 1, wherein the bioactive agent comprises at least one of the following molecules, or an analog or derivative thereof, or a pharmaceutically accept-able salt thereof:





20. (Original) The system of claim 1, wherein the bioactive agent comprises a molecule having substantially the following amino acid sequence of SEQ ID NO:1, or an analog or derivative or conservative substitution variant thereof.


21. (Original) The system of claim 1, wherein the bioactive agent comprises the following molecule having the following amino acid sequence of SEQ ID NO:2, or an analog or derivative or conservative substitution variant thereof.

22. (Original) The system of claim 1, wherein the bioactive agent comprises the following molecule having the following amino acid sequence of SEQ ID NO:3, or an analog or derivative or conservative substitution variant thereof.

23. (Original) The system of claim 1, wherein the bioactive agent comprises one or more of the following molecules, or an analog or derivative thereof, or a pharmaceutically accept-able salt thereof:







24. (Currently Amended) The system of claim 1, wherein the system further comprises:

an ~~international~~ interventional medical device that is adapted to perform a medical procedure at a location associated with the region of tissue.

25. (Currently Amended) The system of claim ~~23~~ 24, wherein the interventional medical device comprises an implantable ~~stem~~ stent.

26. (Currently Amended) The system of claim ~~24~~ 25, wherein the local delivery system comprises a coating on the stent.

27. (Original) A method for treating or preventing atherosclerosis, stenosis, restenosis, smooth muscle cell proliferation, occlusive disease, or other abnormal luminal cellular proliferation condition within a body of a patient, comprising:

locally delivering a bioactive agent at a location within the patient's body;

wherein the bioactive agent is locally delivered at the location in a manner that is adapted to substantially treat or prevent the atherosclerosis, stenosis, restenosis, smooth muscle cell proliferation, occlusive disease, or other abnormal luminal cellular proliferation condition; and

wherein the bioactive agent comprises at least one of CC-1065, duocarmycin, apocynin, RGDfV, RGD pep-tide, resveratrol, a stilbene compound, camptothecin, des-aspartate angiotensin I ("DAA-1"), or apoptosis DNA factor ("ADF"), or an analog or derivative thereof, or a pharmaceutically acceptable salt thereof, or a combination or blend thereof.

28. (Original) The method of claim 27, further comprising:

injuring a wall of a lumen in the patients body; and

wherein the bioactive agent is locally delivered to the location in a manner adapted to substantially treat or prevent restenosis associated with the wall injury.

29. (Original) The method of claim 27, further comprising:
implanting a stent at the location.
30. (Original) The method of claim 29 further comprising:
eluting the bioactive agent from the stem at the location.